BACKGROUND: Shiftwork has been implicated as a risk factor for prostate cancer.
Results from prior studies have been mixed but generally support an association between circadian disruption and prostate cancer. Our aim was to investigate the relationship between shiftwork and prostate-specific antigen (PSA) test obtained as part of the National Health and Nutrition Examination Survey (NHANES) study.
METHODS: We combined three NHANES surveys (2005-2010) to obtain current work schedule among employed men aged 40 to 65 years with no prior history of cancer (except nonmelanoma skin cancer). Men who reported working regular night shifts or rotating shifts were considered shiftworkers. We obtained the total and percentage free PSA test results for these men and dichotomized total PSA into less than 4.0ng/mL or 4.0ng/mL or greater and total PSA of 4.0ng/mL or greater combined with percentage free PSA less than or equal to 25%. Using multivariable logistic regression models, we compared PSA level among current shiftworkers and nonshiftworkers. All statistical tests were two-sided.
RESULTS: We found a statistically significant, age-adjusted association between current shiftwork and elevated PSA at the 4.0ng/mL or greater level (odds ratio = 2.48, 95% confidence interval [CI] = 1.08 to 5.70; P = .03). The confounder-adjusted odds ratio was 2.62 (95% CI = 1.16 to 5.95; P = .02). The confounder-adjusted odds ratio for those with total PSA of 4.0ng/mL or greater and free PSA less than or equal to 25% was 3.13 (95% CI = 1.38 to 7.09; P = .01).
CONCLUSIONS: We observed a strong positive association with shiftwork and elevated PSA level. Our data support the notion that sleep or circadian disruption is associated with elevated PSA, indicating that shiftworking men likely have an increased risk of developing prostate cancer.
Written by:
Flynn-Evans EE, Mucci L, Stevens RG, Lockley SW. Are you the author?
Division of Sleep Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard School of Public Health, Boston, MA; Department of Community Medicine, University of Connecticut Health Center, Farmington, CT.
Reference: J Natl Cancer Inst. 2013 Sep 4;105(17):1292-7.
doi: 10.1093/jnci/djt169
PubMed Abstract
PMID: 23943864
UroToday.com Prostate Cancer Section
